You are here

CP-690-550 Ointment For Chronic Plaque Psoriasis

Last updated on May 9, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Mobile, Alabama, 36606 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Mild to moderate chronic plaque psoriasis (psoriasis vulgaris), with the duration of
at least 6 months;

- A target plaque of at least 9 sq. cm.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Demonstrates "rebound" or "flare" of chronic plaque psoriasis;

- Non plaque form of psoriasis;

- Currently have or history of psoriatic arthritis;

- Current drug induced psoriasis;

- Currently on systemic therapy or was on systemic therapy for psoriasis within the
previous 6 months;

- Currently on phototherapy for psoriasis or was on phototherapy within the previous 3
months

NCT01246583
Pfizer
Completed
CP-690-550 Ointment For Chronic Plaque Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
CP-690-550 Ointment For Chronic Plaque Psoriasis
A Phase 2a, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Pilot Efficacy, Safety, And Pharmacokinetics Of 2 Ointment Formulations Of CP-690,550 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Psoriasis
  • Drug: CP-690,550 Ointment 1
    2% CP-690,550 Ointment 1 twice daily for 4 weeks
  • Drug: Vehicle 1
    Vehicle 1 twice daily for 4 weeks
  • Drug: CP-690,550 Ointment 2
    2% CP-690,550 Ointment 2 twice daily for 4 weeks
  • Drug: Vehicle 2
    Vehicle 2 twice daily for 4 weeks
  • Experimental: Treatment Group A
    Intervention: Drug: CP-690,550 Ointment 1
  • Placebo Comparator: Treatment Group B
    Intervention: Drug: Vehicle 1
  • Experimental: Treatment Group C
    Intervention: Drug: CP-690,550 Ointment 2
  • Placebo Comparator: Treatment Group D
    Intervention: Drug: Vehicle 2
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
71
November 2011
November 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Mild to moderate chronic plaque psoriasis (psoriasis vulgaris), with the duration of at least 6 months;
  • A target plaque of at least 9 sq. cm.

Exclusion Criteria:

  • Demonstrates "rebound" or "flare" of chronic plaque psoriasis;
  • Non plaque form of psoriasis;
  • Currently have or history of psoriatic arthritis;
  • Current drug induced psoriasis;
  • Currently on systemic therapy or was on systemic therapy for psoriasis within the previous 6 months;
  • Currently on phototherapy for psoriasis or was on phototherapy within the previous 3 months
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT01246583
A3921116
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2013

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now